key: cord-0769893-k9t56wbx
authors: Kudhail, Kavina; Thompson, Jacqueline; Mathews, Vivek; Morrison, Breanna; Hemming, Karla
title: Randomised controlled trials in COVID-19 patients: a systematic review and critical appraisal
date: 2022-05-18
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2022.05.034
sha: 6bb4841cd50ea34261a5bdbac545f747d6bd16d4
doc_id: 769893
cord_uid: k9t56wbx

Objectives To describe the prevalence of risks of bias in randomised trials of therapeutic interventions for COVID-19. Study design and setting Systematic review and risk of bias assessment performed by two independent reviewers of a random sample of 40 randomised trials of therapeutic interventions for moderate-severe COVID-19. We used the RoB 2.0 tool to assess risk of bias which evaluates bias under five domains as well as an overall assessment of each trial as high or low risk of bias. Results Of the 40 included trials, 19 (47%) were at high risk of bias, and this was particularly frequent in trials from low-middle income countries (11/14, 79%). Potential deviations to intended interventions (i.e. control participants accessing experimental treatments) were considered a potential source of bias in some studies (14, 35%); as to was the risk due to selective reporting of results (6, 15%). The randomisation process was considered at low risk of bias in most studies (34, 95%); as to was missing data (36, 90%); and measurement of the outcome (35, 87%). Conclusion Many randomised trials evaluating COVID-19 interventions are at risk of bias, particularly those conducted in low-middle income countries. Biases are mostly due to deviations from intended interventions and partly due to the selection of reported results. Use of placebo control and publicly available protocol can mitigate many of these risks.

The COVID-19 pandemic resulted in a surge of medical research, with time-constrained circumstances leading to research conducted at accelerated rates [Mather 2020 ]. For example, the protocols for the platform trials, RECOVERY and Solidarity, were approved within a fraction of the conventional time [Tikkinen 2020 ]. RECOVERY and Solidarity were large multi-centre studies led by experienced researchers, but many smaller, single-centre trials, have also been completed [Karlsen 2020 ]. Whilst a pandemic necessitates a fast response, it also raises the possibility of significant compromises to the methodological quality and rigour of clinical trials [Jung 2021 ]. Poorly conducted trials, which generate biased results, can ultimately translate into ineffective or even harmful treatments, or might mean truly effective treatments disregarded as being ineffective [Schulz 1995] . Not only can such biases lead to detrimental health consequences, but the research can lead to wastage of valuable resources and is unethical [Chalmers 2009; Ioannidis 2014] .

The effects of risks of bias in randomised trials have been well documented and researched before the pandemic [Schulz 1995; Wood 2008] . The number of published randomised trials has been steadily increasing over the years, yet worryingly risk of bias is still high despite having improved over time [Vinkers 2021 ].

For example, allocation concealment and other biases associated with a poorly implemented randomisation have improved; as has the use of trial registration [Savovic 2012; Clark 2016; Vinkers 2021] . Nonetheless, the risk of bias remains a prevalent issue, with publication in a low impact journal and non-blinding being associated with an increased risk of bias [Vinkers 2021 ]. Risks of bias are known to be associated with studies conducted in low-middle income countries [Panagiorou 2013; Wells 2021] ; trials funded for-profit [Panagiorou 2013; Hamm 2010] ; smaller trials [Dechartres 2013] ; and with poor quality of reporting [Tikka 2021 ].

Our objective was to identify randomised trials of COVID-19 interventions and evaluate their risk of bias using a validated assessment tool. The review was out of scope of PROSPERO, but a documented protocol was completed before the review was undertaken [Supplementary Material 1] .

Included studies had to be published after the COVID-19 global outbreak (1 January 2020 onwards), and before the date the search was undertaken (18 June 2021), pre-prints were not included. Due to resource constraints, we determined it possible to undertake the detailed risk of bias review on a random sample of 40 eligible studies and limited these to only those published in English. Eligible studies were fully published randomised superiority trials of therapeutic interventions for COVID-19. To focus on studies only investigating treatment effectiveness rather than drug safety, we only included superiority or phase III or phase IV trials. Information on the trial phase was sought by assessing trial registration data if this was not clear from the published report. Studies with an unknown trial phase were included if they met the eligibility criteria for all other aspects.

Excluded study designs were phase I/II trials, non-randomised trials, cluster-randomised trials, crossover trials, and non-inferiority trials. Study protocols, pilot studies, preliminary trial reports and conference abstracts were also excluded. We restricted study populations to participants with moderate/severe disease who were hospitalised (although trials that included participants with mild COVID-19 were included if they also included moderate/ severe hospitalised participants). Trials investigating any therapeutic treatment of COVID-19 were included. This included traditional Chinese medicine, herbal medications, convalescent plasma, intravenous drugs and oral medication, but excluded prophylactic medication, vaccinations or supportive therapy. No limitations were made based on the type of comparator or number of study arms.

We searched the World Health Organization (WHO) COVID-19 database and the Cochrane COVID-19 study register. The WHO COVID-19 database sources data from over 30 databases, including MEDLINE and PubMed. Similarly, the Cochrane COVID-19 study register sources data from numerous databases, including Embase and Cochrane Central Register of controlled Trials (CENTRAL). These databases have been created for finding COVID-19 related literature only; therefore, using their in-built search filters alone was deemed sufficient. Filters applied to the WHO COVID-19 database ensured studies were clinical trials, had full-text available and were testing 'therapy' interventions. Similar filters were used for conducting the Cochrane COVID-19 study register search (Supplementary Material 2).

Studies identified from the two searches were combined, duplicates were removed, and all studies underwent a title and abstract preliminary screen, followed by a full-text screen. All screening was undertaken independently by two reviewers, with a third opinion taken in cases of disagreement. As a validation step, we used the trials identified in a similar review to confirm that no eligible studies were missed [Zhou 2021] . From those studies assessed to be eligible, we randomly selected a sample of 40 using the random number generator in Excel to undertake the full risk of bias assessment.

We then screened each of the included full trial reports to identify any reference to study protocols or statistical analysis plans. Where none was identified we carried out a google search (full study title and author list) to identify any non-referenced protocols or statistical analysis plans (these did not have to be published). We searched for trial registration documentation for each included study by using any trial registration reported in the text, or using google searches.

Data were collected from the full trial report, and any available protocol, statistical analysis plan or trial registration. Data on study characteristics was collected by one reviewer only. Data for the risk of bias assessment was collected independently by two reviewers. After both assessments were completed, disagreements were identified, and a consensus (henceforth referred to as the joint assessment) was reached by discussion. Study reports were randomly sorted before data collection.

We collected the following trial characteristics: the type of intervention being tested (categorised as immune-based therapy, anti-viral, corticosteroid, or other); the type of comparator (standard of care, placebo, or other intervention); the primary outcome type (classified as symptom severity, mortality, composite or other); and the total realised sample size across all study arms (i.e., the number recruited rather than the number planned at the design stage). In addition, we collected the following characteristics, all because of their prior associations with risk of bias: country of conduct (Asia, Europe, South America, Northeast Africa, United States and multiple regions) to classify as low-middle income country or non-low-middle income country according to the 2020 Gross National Income [Fantom 2016 ]; whether the trial was published in a high impact journal (https://libguides.anu.edu.au/medicine/journals/high-impact); whether a trial protocol, statistical analysis plan or trial registration were available; and whether the trial documented ethical approval and individual participant consent.

We used the RoB2.0 tool to assess risk of bias [Higgins 2016 , accessed June 2021 August 2019] which describes risks of bias under five domains (Table 1) . These risks are identified by a series of signalling questions with a set of elaborations providing extensive detail about how to answer the signal questions [Higgins 2016 ]. Reviewers independently answered each signalling question for each study in turn with full access to the supporting elaboration as an aid. Each signalling question allows an assessment of "yes", "probably yes", "no", "probably no", and "no information". This assessment was made for what was considered the primary outcome of the study and assuming interest in the effect of assignment to the intervention (as opposed to the effect of adhering to the intervention). After the independent assessment of the signalling questions, the two independent reviewers resolved any discrepancies. This then formed the joint assessment. These joint assessments are summarised in a series of supplementary tables describing all responses under the signalling questions. In the tabulated results, we combine the classification of "probably yes" with "yes" and "probably no" with "no". Following RoB2.0, these joint responses to the signalling questions were mapped onto a risk of bias assessment for each domain, classifying trials as "low risk of bias", "some concerns", or "high risk of bias". Finally, again following RoB2.0 we created an overall study assessment of risk of bias: a study is judged at high risk of bias if it is assessed at high risk in at least one domain or some concerns for multiple domains; low risk of bias if it is assessed as low risk in all domains; and some concerns otherwise.

We describe the assessment of risk of bias (based on the joint assessment) for all domains and signalling questions, using simple descriptive statistics (numbers and percentages). For the overall assessment of bias, we summarise by the following characteristics (all identified elsewhere to be risk factors for bias): (i) those without a placebo control; (ii) those without a publicly available protocol or statistical analysis plan; (iii) trials with a sample size less than 150 (the median sample size in the sample). (iv) low-middle income countries; and (v) non-high impact journals.

Finally, we describe the reliability of the independent assessments by computing the percentage agreement (including raw percentage agreement and a weighted Gwet's AC value [Gwet 2014; Wongpakaran 2013] ) between the two independent assessments for each of the five domains. Reliability was computed across an ordinal three-point scale (high risk of bias / some concerns /low risk of bias).The Gwet's AC statistic was weighted with the penalisation (weights) set to thirds: low penalisation set to 2/3 for high-some concerns, low-some concerns and anything-unclear; and high penalisation set to 1/3 for high-low concerns.

Searches were conducted on 18th June 2021, yielding a total of 1,628 citations from the two databases. After 151 duplicated articles were removed, 1,477

were assessed for title and abstract screening (Figure 1) . A further 1,323 were removed, leaving 154 studies for full-text screening. A total of 69 of these trials were identified as eligible for inclusion (with reasons for exclusion provided in Figure 1 ). No additional studies were added after assessing the validation systematic review reference list. From this, a subset of 40 studies were randomly sampled to form the sampling frame (Supplementary Material 3).

Of the 40 included trials, many were conducted in Asia (18, 45%); some in Europe (7, 17%); 6 (15%) in South America; 2 (5%) in Northeast Africa; 1 (3%) study was conducted in the United States; and 6 (15%) studies were conducted across multiple regions. Around a third were conducted in low-middle income countries (14, 35%). The trials included a range of different therapeutic interventions: immune-based therapy (9, 23%), anti-viral (8, 20%) and corticosteroids (5, 12%). The majority compared against standard of care (26, 65%) with only 25% (10) including a placebo control. A minority compared against another therapeutic intervention (4, 10%). The most commonly reported primary outcome type was symptom severity (24, 60%), with mortality being the primary outcome in 7 (18%) studies. Almost all studies were registered (37, 93%), and half had a publicly available protocol or statistical analysis plan (20, 50%). The average realised sample size was 150 (IQR: 89-379). All studies reported obtaining ethical approval and consent.

Only 10 (25%) of the studies were assessed to be at low risk of bias; 19 (47%) were assessed at high risk of bias, and 11 (28%) were assessed as having some concerns. The majority of trials were assessed as low risk of bias due to the randomisation process (34, 85%); bias due to missing data (36, 90%) and bias due to measurement of the outcome (35, 87%). In contrast, fewer trials were assessed as low risk of bias due to deviations from the intended interventions (16, 40%) and due to selection of the reported result (21, 52%).

Almost all studies used a clearly reported random allocation method (37, 93%), and in most (32, 80%) it was clear that the allocation had been properly concealed before the consent process (Supplementary Table 1 ). In only a small number of trials (3, 7%) was any baseline imbalance identified (by the reviewers), which might indicate a poorly implemented randomisation process.

In many trials, the participants (27, 67%) and their carers or people delivering the intervention (29, 72%) were aware of the assigned interventions (Supplementary Table 2 ). In some trials (15, 37%), it was assessed that this knowledge could have led to deviations from the intended interventions; and that these deviations could have affected the outcome (11, 27%). In some trials (3, 7%), these deviations were assessed to affect one of the intervention arms more than the other. Most trials (31, 77%) carried out an analysis to appropriately estimate the effect of the assignment to the intervention (i.e., an intention to treat analysis), and in only a few studies (5, 13%) was it assessed that any deviations to assigned interventions could have had a substantial impact.

In most trials (32, 80%), the outcome data were available for all, or nearly all, of the participants (Supplementary Table 3 ). However, in a minority of trials (7, 17%), it was assessed as possible that missing outcomes might have been biased by the missing data, perhaps because the missingness might depend on the outcome (4, 10%).

In most studies, the method of measuring the outcome was assessed to be appropriate (37, 93%), and only occasionally (2, 5%) was it assessed that the measurement of the outcome could have differed across the study arms (Supplementary Table 4 ). However, outcome assessors were often aware of the allocated study arm (17, 43%), although this was not considered to have influenced outcome assessment in any studies.

Whilst in over half of the studies (24, 60%), it was assessed that the data were analysed according to a pre-specified approach, in many studies (12, 30%), this was unclear (Supplementary Table 5 ). In a number of studies (9, 23%), it was assessed as possible that there were multiple eligible outcomes (i.e., the scale, cut points, assessment times were not clearly defined), and in a few studies (2, 5%) it was assessed as possible that there had been multiple analyses of the data, but in many studies (17, 43%) no information on pre-specification was provided.

When investigating whether there was a tendency for trials with certain characteristics to be at increased risk of bias (compared to the 47% classified as at-risk overall 40 trials), we identified the likelihood of high risk of bias was 57% (17/30) in those trials without the inclusion of a placebo control; 60% (12/20) in those trials without a publicly available protocol or statistical analysis plan; 60% (12/20) in small trials (sample size <150); 79% (11/14) in those from low-middle income countries and 64% (14/22) in those in a non-high impact journal.

Agreement between the two independent assessments varied across the domains, and was greater for the randomisation process (Gwet AC: 71.5 95% CI: 52.1, 

We identified that a substantial proportion of the randomised trials of COVID-19 interventions published over the first 18 months of the pandemic are at risk of bias. We identified that these risks are mostly due to risks around deviations from the intended intervention (e.g., control arm participants receiving the active intervention); and that risks of bias were particularly prevalent in studies conducted in low-middle income countries. Other risks of bias, such as those due to selection of the reported result or measurement of the outcome, were much lower but nonetheless still prevalent in a significant minority of the studies.

Modifiable factors that will reduce these risks are using a placebo control and publicly available protocol: only half of the trials had a publicly available protocol, and only a quarter used a placebo control.

High-quality evidence is always important, particularly in the context of a pandemic [Raynaund 2021] . Evidence is emerging that many COVID-19 trials are of poor quality: reviews of registered COVID-19 trials (as opposed to fully published studies) have revealed that many are not blinded and have many other features associated with poor quality [Mehta 2020; Pundi 2020; Zhu 2020 , Karlsen 2020 Mainoli 2021 , Jung 2021 ]. In addition, there is evidence that many studies of traditional Chinese medicine for COVID-19 are also at risk of bias Gao 2020] ; and where risk of bias has been investigated in the context of specific treatments (e.g., hydroxychloroquine) concerns have been raised of the lack of high-quality studies [Mazhar 2020]. Moreover, the BMJ living systematic review investigating treatments for COVID-19 also conducted a risk of bias assessment using a revised version of the Cochrane RoB2.0 tool, and found most studies (~60%) to have a high risk of bias [BMJ 2020] . Our findings here also support those of another risk of bias assessment using the older version of the Cochrane Risk of Bias tool but for which the assessment was not conducted in duplicate [Zhao 2021 ]; and are not dissimilar to assessments of trials in settings other than COVID-19 [Turner 2013; Hamm 2020; Vinkers 2021] .

The importance of blinding: The most common source of bias identified in this review was that due to deviations from intended interventions. Bias due to deviations of intended interventions, also known as performance bias, is unlikely to affect fully blinded trials [Porta 2014 ]. This bias refers to the use of other complementary interventions differentially across study arms in a way that would not happen outside a trial context; or the use of the active intervention in the control arm. Others have argued that blinding is not desirable in pragmatic trials where the objective is to estimate effect in real-world conditions [Mansournia, 2017] . In pragmatic trials the interest is not in the isolated effect of the intervention, but rather how it works in its proposed context [Christian 2020 ]. Arguably the COVID-19 trials included in this review were all wanting to estimate effects in "real-world conditions". Indeed, any non-adherence to the active intervention was not considered a deviation in our assessment of risk of bias, in line with pragmatic intent [Higgins 2019 ]. However, a bias can arise, even in pragmatic trials when for example, complementary interventions (such as the use of other experimental concomitant therapies in COVID-19 patients) is differentially used across trial arms, because of a perceived rather than real need [Henderson 2007 ]. This type of bias very possibly affected one of the recovery trials -where 17% of patients in the usual care group were given azithromycin (the active intervention) or another macrolide antibiotic [RECOVERY 2021] . It can thus be very important in so-called pragmatic trials to blind therapeutic interventions to prevent these sorts of biases, and when blinding is not possible reporting post-randomisation treatments by arm can aid identification of this sort of bias. Relatedly, in the situation of possible side effects due to the active intervention, controls can be very important to prevent the possibility of unblinding when side effects occur [Jensen 2017 ].

Three large, multi-centre pragmatic trials (RECOVERY, Solidarity and ACTT) are widely hailed as exemplary designs, cutting red tape, delivering fast and promoting collaboration [Tikkinen 2020 ]. Yet, both the RECOVERY and Solidarity trials were assessed as having some concerns in our review and at high risk of bias by the BMJ living systematic review [BMJ 2020] . For both, this assessment of high risk of bias was because of potential deviations to intended interventions, arising because of the unblinded nature of the studies. The ACTT trial, also large, pragmatic and timely, was blinded, and so is unlikely to be at risk of bias due to deviations from intended interventions [Beigel 2020]. For one drug compared in these trials, remdesivir, the (unblinded) Solidarity trial [WHO Solidarity Trial] and the (blinded) ACTT trial [Beigel 2020] give conflicting results. Direct conflict of study results, such as this, especially when one of the studies is unblinded creates uncertainty -particularly in the case where the unblinded trial (sample size in Solidarity ~ 11,000) is much larger than the blinded trial (sample size in ACTT ~1,000).

The Cochrane Risk of Bias tool is a generic tool designed to be used across a range of randomised trials, and whilst broadly general does not, for example, consider aspects which might relate only to certain types of trials, for example, platform trials for which there can be other specific concerns around biases [Normand 2021] . We applied the risk of bias assessment only to the primary outcome and only to ascertain the risk against the effect of assignment to the intervention. Risks of bias might differ for other outcomes, although arguably, the primary outcome should be considered more important. Interest might reasonably be in the effect of adhering to the treatment (efficacy as opposed to effectiveness), particularly in earlier phases of treatment assessment [Hernan 2017 ]. Whilst our assessment was performed independently by two reviewers, the agreement between the independent assessments was low for those domains where risk of bias was assessed as a potential concern (deviations from intended interventions and selection of reported results). These discrepancies likely represent a real uncertainty around whether bias is, or is not, present. This low agreement might be considered a further indicator of potential bias or poor reporting [Hartling 2013 ]. Our assessment included only 40 of 69 eligible studies. These 40 studies represent a random sample of those eligible, and as we are not identifying risk of bias to inform treatment decision, this review can nonetheless inform on the likely risk of bias in trials of COVID-19 interventions more generally.

High-quality, low risk of bias randomised trials are fundamental to responding to a pandemic. Several large platform trials are exemplary in their timeliness and collaborative nature. Nonetheless, many smaller trials have been initiated. A large majority of published trials testing COVID-19 treatments are at high risk of bias, particularly those in low-middle income countries. Even the handful of trials considered exemplary might be at risk of bias, mostly because of their unblinded nature. To ensure patients receive effective treatments, future randomised trials must be designed to be at low risk of bias to avoid wastage of research and spurious findings.

There are no conflicts of interest to declare

There is no funding to declare Ethical Approval statement No ethical approval was obtained Randomisation creates (on average) an even distribution of participants across the study arms. To achieve this, the randomisation must both be truly random, and it must be fully concealed at the time of recruitment. A poorly implemented randomisation can manifest as notable differences in the characteristics of participants across the study arms. Domain 2: Risk of bias due to deviations from the intended interventions.

Participants should have been offered these interventions to evaluate the comparative effect of two interventions. Deviations in the uptake of this offer are usually not a concern when interest is in the effect of the intervention when some participants will naturally not want the intervention, for example, due to side effects or the way it is administered. The use of other concomitant interventions in both arms (background care) should be the same across both study arms. Problems arise when with knowledge of the participation in a study, particularly what intervention the participant is receiving, selectively lead to differences in this background care across the study arms. Domain 3: Risk of bias due to missing outcome data.

To evaluate the effect of the assignment to the intervention outcome, data are required on all randomised participants, even those who decline the offer of the intervention. Small amounts of missing outcome data, evenly distributed across study arms, are unlikely to be problematic. Problems arise when the amount of missing data is more substantial, and it differs across the study arms. Of note, bias can still arise when the proportion of missing outcome data is similar across study arms, but the characteristics of those with missing data differs across the arms. Domain 4: Risk of bias in the measurement of the outcome.

Assessment and measurement of the outcome should not be influenced or differ across the treatment arms. If those who are measuring the outcome have knowledge of the treatment arm, this may unintentionally affect the way the outcome is measured if there is any subjectivity involved in the outcome assessment. Domain 5: Risk of bias in selection of the reported results.

Clear specification of a primary outcome mitigates the problem of selecting outcomes that are apparently different, but this difference reflects a chance finding. To achieve this the primary outcome must be clearly specified, including how it will be measured, scales which will be used, any cut points that will be used and when it will be measured (primary assessment time). Likewise, a clear primary analysis method should be specified, which includes how any covariates will be adjusted for in the analysis.

High 

COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine

Drug treatments for COVID-19: living systematic review and network meta-analysis

Avoidable waste in the production and reporting of research evidence

Masking in Pragmatic Trials: Who, What, and When to Blind

Allocation concealment in randomised controlled trials: are we getting better?

Influence of trial sample size on treatment effect estimates: meta-epidemiological study

Serious Concerns About the RCT Study Quality of Traditional Chinese Medicine Injections for Treating Cardiovascular Diseases and COVID-19. Cardiovasc Drugs Ther

Handbook of Inter-Rater Reliability: The Definitive Guide to Measuring the Extent of Agreement Among Raters

The World Bank's Classification of Countries by Income

Testing the risk of bias tool showed low reliability between individual reviewers and across consensus assessments of reviewer pairs

A descriptive analysis of a representative sample of pediatric randomized controlled trials

Clinical trials and medical care: defining the therapeutic misconception

Per-Protocol Analyses of Pragmatic Trials

A revised tool for assessing risk of bias in randomized trials

Increasing value and reducing waste in research design, conduct, and analysis

Active placebo control groups of pharmacological interventions were rarely used but merited serious consideration: a methodological overview

Methodological quality of COVID-19 clinical research

A systematic review of trial registry entries for randomized clinical trials investigating COVID-19 medical prevention and treatment

Analysis of clinical and methodological characteristics of early COVID-19 treatment clinical trials: so much work, so many lost opportunities

Biases in randomized trials: a conversation between trialists and epidemiologists

Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials?

Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis

Comparative effect sizes in randomised trials from less developed and more developed countries: meta-epidemiological assessment

COVID-19-related medical research: a meta-research and critical appraisal

Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

COVID-19 clinical trials: learning from exceptions in the research chaos

Quality of reporting and risk of bias: a review of randomised trials in occupational health

The evolution of assessing bias in Cochrane systematic reviews of interventions: celebrating methodological contributions of the Cochrane Collaboration

reveals a positive trend but also an urgent need for improvement

Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results

An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries

A comparison of Cohen's Kappa and Gwet's AC1 when calculating inter-rater reliability coefficients: a study conducted with personality disorder samples

Evaluating the methodology of studies conducted during the global COVID-19 pandemic: A systematic review of randomized controlled trials

Systematic review of the registered clinical trials for coronavirus disease 2019 (COVID-19)

 Table 3 : Risk of bias assessment by broad domains of risk 1 Overall risk of bias judgement: low risk of bias is defined as all domains at low risk of bias; some concerns is defined as at least one domain has some concerns but does not include any high risk of bias for any domain; and high risk of bias is defined as high risk of bias in at least one domain or some concerns for multiple domains; * 0 domains at risk includes 1 at low risk and 2 with some concerns (overall risk). Gwet (47) Number of domains at high risk 0* 21 (53) 1 4 (10) 2 14 (35) 3 4 (10) 4 2 (5) 5 6 (15) 21 statistic is weighted (see methods) to give more weight to disagreements between low and high risk compared to some concerns 22